Sherly Purnamawaty


Acute myocardial infarction (IMA) is the most severe manifestation of coronary arterial disease and about 60%-75% of IMA is NSTEMI. Complications are associated with high mortality rates so predicting the development of complications in NSTEMI will help physicians improve risk stratification and determine optimal treatment. Suppression of tumorigenicity-2 (ST2) is a family of interleukin-1 (IL-1) receptors. Ischemia, injury and myocardial infarction will cause cardiomyocytes release sST2, associated with a worse prognosis. This study used a prospective cohort method conducted on NSTEMI patients treated at Pusat Jantung Terpadu of RSUP. Dr. Wahidin Sudirohusodo during the period of March 2019. A sample of 42 patients was obtained. All patients were tested for sST2 levels by immunochromatography and followed up during hospitalization. Data taken during follow-up are the development of heart failure, arrhythmia, cardiogenic shock, sudden cardiac arrest, length of stay, and outcome. Data were analyzed statistically by Mann Whitney and Spearman test. The results of sST2 level in NSTEMI with heart failure were 114.09±92.01 ng/mL and without heart failure was 58.94±57.75 ng/mL (p=0.014). There was no significant difference between sST2 levels in NSTEMI with complications of arrhythmias, cardiogenic shock, and sudden cardiac arrest compared to patients without those complications (p>0.05). The level of sST2 was significantly higher in NSTEMI patients who died (164.05±77.35 ng/ml) than those survived (72.55±73.15 (p=0.027). There was no correlation between sST2 levels and length of stay (p=0.947). It was concluded that sST2 levels can be a prognostic marker for NSTEMI particularly heart failure and outcome.


NSTEMI, sST2, heart failure, arrhythmia, cardiogenic shock, sudden cardiac arrest, mortality


Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. The Lancet. 2017; 389(10065): 197-210.

World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. Global Atlas on Cardiovascular Disease Prevention and Control. 2011; 8-13.

Mullasari AS, Balaji P, Khando T. Managing complications in acute myocardial infarction. J Assoc Physicians India. 2011; 59:43-8.

Bajaj A, Sethi A, Rathor P, Suppogu N, Sethi A. Acute complications of myocardial infarction in the current era: diagnosis and management. Journal of investigative medicine. 2015; 63(7):844-855.

Bahit MC, Lopes RD, Clare RM, Newby LK, Pieper KS, Van de Werf F, et al. Heart failure complicating non–ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. JACC: Heart Failure. 2013; 1(3): 223-229.

Roubín S, Abu-Assi E, López-López A, Bouzas-Cruz N, Castiñeira-Busto M, Cambeiro-González, et al. Risk stratification for the development of heart failure after acute coronary syndrome at the time of hospital discharge: predictive ability of GRACE risk score. Journal of cardiology. 2015; 66(3): 224-231.

Salvagno GL and Pavan C. Prognostic biomarkers in acute coronary syndrome. Annals of translational medicine. 2016; 4(13): 1-8.

Demyanets S, Speid WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014; 9(4): e95055.

Konukoglu D. Is soluble ST2 a new marker in heart failure?. International Journal of Medical Biochemistry. 2018; 1(1): 44-51.

Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. Journal of the American College of Cardiology. 2014; 63(2):158-166.

Richards AM, Di Somma S, Mueller T. ST2 in stable and unstable ischemic heart diseases. The American journal of cardiology. 2015; 115(7): 48B-58B.

Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, James SK. ST2 and mortality in non–ST-segment elevation acute coronary syndrome. American heart journal. 2010; 159(5): 788-794.

Barbarash O, Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Akbasheva O, et al. Prognostic value of soluble ST2 during hospitalization for ST-segment elevation myocardial infarction. Annals of laboratory medicine. 2016; 36(4): 313-319.

Aldous SJ, Richards AM, Troughton R, Than M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. Journal of cardiac failure. 2012; 18(4): 304-310.

Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Annals of translational medicine. 2016; 4(13).

Kytö V, Sipilä J, Rautava P. Association of age and gender with risk for non-ST-elevation myocardial infarction. European journal of preventive cardiology. 2015; 22(8): 1003-1008.

Hamm CW, Heeschen C, Falk E, Fox KA. Acute Coronary Syndromes: Pathophysiology, Diagnosis and Risk Stratification. 2014

Lapu-Bula R, Onwuanyi A, Bielo MV, Deffer O, Quarshi A, Alema-Mensah E, et al. Risk factors for acute non-ST-segment elevation myocardial infarction in a population sample of predominantly African American patients with chest pain and normal coronary arteries. Ethnicity & disease. 2011; 21(4): 421.

Hubacek JA, Stanek V, Gebauerova M, Adamkova V, Lesauskaite V,

Zaliaduonyte-Peksiene D, et al. Traditional risk factors of acute coronary syndrome in four different male populations–total cholesterol value does not seem to be relevant risk factor. Physiol Res. 2017; 66(1): S121-S128.

Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 in non ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012; 58:257e266.

Bhardwaj A and Januzzi JL. ST2: a novel biomarker for heart failure. Expert review of molecular diagnostics. 2010; 10(4): 459-464.

Hashimoto T and Kass DA. Stressed hearts inflame the body (in a good way). Proceedings of the National Academy of Sciences. 2015; 112(23): 7113-7114.

Ciccone MM, Cortese F, Gesuald M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: a review. Molecules. 2013; 18(12): 15314-15328.

Chen LQ, de Lemos JA, Das SR, Ayers CR, Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clinical Chemistry. 2013; 59(3): 536-546.



  • There are currently no refbacks.